Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
Q4 2023 vs. Q3 2023
How the institutions holding Definium Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 93 | 1 | 104 | +12 |
| Shares | 3.88M | 610 | 4.88M | +1.01M (+26.0%) |
| Value | $12.1M | $1.91K | $17.9M | +$5.74M (+47.3%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (21)
Institutions that held Definium Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 600,000 | $2.20M | 0.60% |
| Boothbay Fund Management, LLC | 146,660 | $536.8K | 0.02% |
| Scotia Capital Inc. | 121,756 | $441.1K | 0.00% |
| Moloney Securities Asset Management, LLC | 69,511 | $254.4K | 0.04% |
| XTX Topco Ltd | 23,935 | $87.6K | 0.02% |
| Mitchell McLeod Pugh & Williams Inc | 20,000 | $73.2K | 0.02% |
| Bailard, Inc. | 17,300 | $63.3K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 16,853 | $61.7K | 0.01% |
| NVWM, LLC | 416 | $1.52K | 0.00% |
| Fairman Group, LLC | 85 | $311 | 0.00% |
| Signature Resources Capital Management, LLC | 53 | $194 | 0.00% |
| Louisbourg Investments Inc. | 52 | $190 | 0.00% |
| American Capital Advisory, LLC | 33 | $121 | 0.00% |
| Vima LLC | 19 | $70 | 0.00% |
| Northwestern Mutual Wealth Management Co | 16 | $59 | 0.00% |
| Castleview Partners, LLC | 16 | $59 | 0.00% |
| Advisory Services Network, LLC | 9 | $33 | 0.00% |
| Steward Partners Investment Advisory, LLC | 6 | $22 | 0.00% |
| Hexagon Capital Partners LLC | 4 | $15 | 0.00% |
| Rothschild Investment LLC | 3 | $11 | 0.00% |
| Coppell Advisory Solutions LLC | 1 | $4 | 0.00% |
Sold out (9)
Institutions that held Definium Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Virtu Financial LLC | 28,494 | $89.0K |
| GTS Securities LLC | 19,854 | $62.1K |
| North Star Investment Management Corp. | 14,860 | $46.5K |
| Marshall Wace, LLP | 11,545 | $36.1K |
| Creative Planning | 218 | $683 |
| Impact Partnership Wealth, LLC | 48 | $150 |
| FinTrust Capital Advisors, LLC | 33 | $104 |
| Gradient Investments LLC | 18 | $56 |
| VisionPoint Advisory Group, LLC | 16 | $50 |
Not filed for Q4 2023 yet (1)
Institutions that held Definium Therapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Column Capital Advisors, LLC | 610 | $1.91K |